Jason D. Lickliter - Concepedia

Author

Jason D. Lickliter

Also Known As

Charlotte Lemech, Cho, Jong Moon, Indika Leelasena, J D Lickliter, J. D. Lickliter, J. Lickliter, J.D. Lickliter, Jason D Lickliter, Jason D. Lickliter, Jason Lickliter

145

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

The University of Queensland QIMR Berghofer Medical Research Institute The University of Melbourne The University of Western Australia Breast Cancer Network Australia

About

Jason D. Lickliter is an author at The University of Queensland specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	22	2.1K
2	Cell Biology	6	6	478
3	Health Sciences	3	3	109
4	Engineering	2	2	177
5	Biomedical Engineering	1	1	112

Jason D. Lickliter

Publications

4.7K

Citations

H-Index

Page 1

	Year	Citations
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine Cheryl Keech, Gary Albert, Iksung Cho, New England Journal of Medicine	2020	1.2K
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial Michael Weller, Nicholas Butowski, David Tran, The Lancet Oncology Egfrviii-expressing GlioblastomaNeuro-oncologyAct IvGliomaInternational Phase 3	2017	1.1K
EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme Bryan W. Day, Brett W. Stringer, Fares Al‐Ejeh, Cancer Cell Neuro-oncologyGliomaGlioblastoma MultiformeEpha3 Maintains TumorigenicityMedicine	2013	214
First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma James R. Whittle, Jason D. Lickliter, Hui Gan, Journal of Clinical Neuroscience NanomedicineNeuro-oncologyDrug TargetingEngineeringTherapeutic Nanomaterials	2015	112
A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease Michael Grundman, Roger Morgan, Jason D. Lickliter, Alzheimer s & Dementia Translational Research & Clinical Interventions	2018	106
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours Keith Dredge, Todd V. Brennan, Edward Hammond, British Journal of Cancer	2018	98
Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial Angus H. Forster, Katey Witham, Alexandra C. I. Depelsenaire, PLoS Medicine	2020	91
Safety, Tolerability, and Pharmacokinetics of ARC‐520 Injection, an RNA Interference‐Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers Thomas Schluep, Jason D. Lickliter, James Hamilton, Clinical Pharmacology in Drug Development	2016	83
Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects Kai-Yang Tang, Jason D. Lickliter, Zhihua Huang, Cellular and Molecular Immunology InflammationCytokineAutoimmune DiseaseHealthy SubjectsMedicine	2018	83
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial Raburn M. Mallory, Neil Formica, Susan Pfeiffer, The Lancet Infectious Diseases VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing	2022	78

Page 1